Panacea Biotec Valuation
Is 531349 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 531349 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 531349's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 531349's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 531349?
Key metric: As 531349 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 531349's PS Ratio? | |
|---|---|
| PS Ratio | 4.7x |
| Sales | ₹5.50b |
| Market Cap | ₹26.11b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.5x |
| Enterprise Value/EBITDA | 1154.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 531349's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.7x | ||
524669 Hester Biosciences | 7.1x | n/a | ₹20.2b |
532039 Zenotech Laboratories | 12.7x | n/a | ₹4.7b |
NIRMAN Nirman Agri Genetics | 1.6x | n/a | ₹2.4b |
524663 Bharat Immunologicals & Biologicals | 13.3x | n/a | ₹1.0b |
531349 Panacea Biotec | 4.7x | n/a | ₹25.1b |
Price-To-Sales vs Peers: 531349 is good value based on its Price-To-Sales Ratio (4.7x) compared to the peer average (8.7x).
Price to Sales Ratio vs Industry
How does 531349's PS Ratio compare vs other companies in the Asian Biotechs Industry?
| 72 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 72 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 531349 is good value based on its Price-To-Sales Ratio (4.7x) compared to the Asian Biotechs industry average (9x).
Price to Sales Ratio vs Fair Ratio
What is 531349's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 4.7x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 531349's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Venus Remedies
₹3.9b
Engages in the pharmaceutical business in India and internationally.
VENUSREM
₹294.55
7D
-0.4%
1Y
-21.5%
Vivimed Labs
₹410.4m
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.
VIVIMEDLAB
₹4.95
7D
0%
1Y
-45.9%
Granules India
₹135.5b
Manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly.
532482
₹574.50
7D
8.6%
1Y
48.3%